Biocon Share Price in Focus Today: Biocon Gets FDA Approval for Bevacizumab Biosimilar

Posted by : sachet | Fri Apr 11 2025

Biocon Share Price in Focus Today: Biocon Gets FDA Approval for Bevacizumab Biosimilar

Biocon Share Price is up by 3.41% or ₹10.30, reaching ₹316.60 today on 11th April 2025. Based on the recent news updates, investors gained high confidence in Biocon shares for the near and long term. 

Share Market Today, Stocks in news: Biocon Biologics Limited, a subsidiary of Biocon Limited, has received an FDA approval for Jobevne (Bevacizumab Biosimilar) for cancer therapy. The approval was obtained on 10th April 2025, marking the company’s 7th approval in the United States. It strengthens Biocon Limited’s leadership in affordable oncology solutions. 

Strong Clinical Evidence for FDA Approval

Here are the elements that influenced the FDA’s decision to approve Biocon’s Bevacizumab Biosimilar:

  • Pharmacokinetics
  • Immunogenicity
  • Nonclinical and Functional Data
  • Safety and Efficacy
  • Structural and Analytical Similarity

FDA’s approval confirmed no clinically meaningful differences between Jobevne and Avastin. It met the high standards required for biosimilar approval in the United States.

What Biocon’s CEO Says?

“This marks our third U.S. FDA approval for an oncology biosimilar and the seventh overall. It significantly strengthens our oncology portfolio and reiterates our commitment to providing affordable access to life-saving biologics in the U.S. and globally,” ~ Shreehas Tambe (CEO & Managing Director of Biocon Biologics).

Biocon Biologics: Leading Biosimilar Innovation

Biocon operates in 120+ countries and acts as a global trailblazer in biosimilar and insulin manufacturing. Its end-to-end capabilities, from research development to commercialisation, make it one of the few companies worldwide capable of delivering lab-to-market biosimilar innovation at scale. The global infrastructure of Biocon includes:

  • R&D Centers
  • Strategic Alliances
  • State-of-the-Art Manufacturing Units

Biocon Biologics Limited is strategically positioned to emerge as a dominant force in the US Biosimilar market, which is projected to reach $40 billion by 2030. 

Summary

The FDA approval of Jobevne is a major achievement for both Biocon Biologics and the global healthcare community. With biosimilars playing an increasingly vital role in reducing healthcare expenses, Biocon’s expanding presence in critical therapeutic segments such as cancer ensures that patients across the United States and the globe have greater access to life-saving therapies.

Biocon Biologics’ latest achievement brings fresh confidence to the future of biosimilar drugs, which are low-cost, effective, and available.

For live stocks updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities. 

Explore Other News Articles

Stock Market Today: Sensex Jumps 1,100 Pts: Nifty Scales 22,800 as Gains Extend; Check Details

Stocks to Watch Today: 11th April 2025 | Sun Pharma, RITES, BHEL, TATA MOTORS, NBCC, SRF & More!

TCS Q4 Results Miss Estimates: Net Profit Down 2% YoY | ₹30 Dividend Declared

Tata Capital Files ₹15,000 Crore IPO via Confidential DRHP | Check All Details Here

BoAt’s Imagine Marketing Filed ₹2,000 Crore IPO via Confidential Route | Check All Details Here

Is the Indian Stock Market Closed Tomorrow on Mahavir Jayanti 2025? Check Details Here

Suzlon Share Price Falls 3.05% Amid Order Cancellations and Selloffs

Zomato Rebrands to Eternal Limited: Stock Opened Higher at ₹216 Amid COO Exit

icon

100% Safe & Secure Platform.

Univest encrypts all data and transactions to ensure a completely secure experience for our members.

Copyright

2025 Univest. All rights reserved. | Designed with ❤️ in India
Univest Stock Broking
Univest Stock Broking Private Limited - SEBI Reg. No. INZ000317437 (Stock Broker), NSE TM Code: 90392, BSE TM Code: 6866, MCX TM Code: 57290 and ICCL- Self Clearing Member Code: 6866, SEBI Reg. No. IN-DP-779-2024 (Participant), NSDL DP ID: IN304748.
 Risk Disclosures on Derivatives
⬤ 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
⬤ On an average, loss makers registered net trading loss close to ₹ 50,000
⬤ Over and above the net trading losses incurred, loss makers expended an additional 28% of
net trading losses as transaction costs.
⬤ Those making net trading profits, incurred between 15% to 50% of such profits as transaction
cost.
Attention Investors: As per NSE circular dated July 6, 2022: https://nsearchives.nseindia.com/content/circulars/INSP52900.pdf, BSE circular dated July 6, 2022: https://www.bseindia.com/markets/MarketInfo/DispNewNoticesCirculars.aspx?page=20220706-55, MCX circular dated July 11, 2022: https://www.mcxindia.com/docs/default-source/circulars/english/2022/july/circular-418-2022.pdf?sfvrsn=9401991_0, investors are cautioned to abstain them from dealing in any schemes of unauthorised collective investments/portfolio management, indicative/ guaranteed/fixed returns / payments etc. 
Investors are further cautioned to avoid practices like:
a. Sharing 
i) trading credentials – login id and passwords including OTPs.
ii) trading strategies,
iii) position details.
b. Trading in leveraged products /derivatives like Options without proper understanding, which
could lead to losses.
c. Writing/ selling options or trading in option strategies based on tips, without basic knowledge
and understanding of the product and its risks.
d. Dealing in unsolicited tips through platforms like Whatsapp, Telegram, Instagram, YouTube,
Facebook, SMS, calls, etc.
e. Trading / Trading in “Options” based on recommendations from unauthorised / unregistered
investment advisors and influencers.
 Kindly read the Advisory Guidelines For Investors as prescribed by the Exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client’s assets: https://nsearchives.nseindia.com/content/circulars/INSP49434.pdf
Kindly, read the advisory as prescribed by the Exchange with reference to their circular: NSE/ISC/51035 dated January 14, 2022 regarding Updation of mandatory KYC fields by March 31, 2022: https://www.nseindia.com/resources/exchange-communication-circulars# 
Attention Investors: Prevent unauthorised transactions in your Demat account by updating your mobile number with your depository participant. Receive alerts on your registered mobile number for debit and other important transactions in your Demat account directly from NSDL on the same day. Prevent unauthorised transactions in your Trading account by updating your mobile numbers/email addresses with your stock brokers. Receive information on your transactions directly from the Exchange on your mobile/email at the end of the day. Issued in the interest of investors. KYC is a one-time exercise while dealing in securities markets - once KYC is done through a SEBI-registered intermediary (Broker, DP), you need not undergo the same process again when you approach another intermediary. As a business, we don’t give stock tips and have not authorised anyone to trade on.
About Univest
About: Univest is a cutting-edge stock market platform designed to help traders and investors maximize their returns with expert-driven advisory services and seamless trading execution. Whether you're a seasoned trader or just starting, Univest simplifies your investment journey with actionable trade recommendations, AI-powered portfolio insights, and a fully integrated brokerage experience. With Univest, you gain access to proven stock market advisory, offering expert trade ideas for stocks, futures, options, and commodities. Our one-click trade execution feature eliminates slippage, ensuring instant execution through our advisory-first brokerage. Smart portfolio management allows you to identify underperforming stocks, optimize your investments, and receive real-time alerts. Additionally, Univest provides seamless investment opportunities beyond stocks, including mutual funds, bonds, fixed deposits, and insurance (coming soon). Join over 40 lakh active investors who trust Univest to make informed and profitable trading decisions. Start investing smarter today! 🚀  
Attention Investors : To ensure a smooth trading experience and prevent unauthorized transactions, investors must update their mobile number and email ID with their stockbroker or depository participant. As per regulatory requirements, investors are required to pay a stipulated amount as an upfront margin for trading in the Cash/FO segment. We encourage all investors to regularly check their securities in the Consolidated Account Statement (CAS) issued by depository to verify their holdings.Always verify alerts and transaction details received directly from the exchange or NSDL before proceeding with any trades. Please do not make payments through unverified email links, WhatsApp, or SMS. Always trade through a registered stockbroker and verify all details before making financial decisions.
 
Disclaimer: Investments in the securities market are subject to market risks. Please read all related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit. For more disclaimer /disclosure, visit https://univest.in/stock-broker or Univest App.We collect and use your contact information for legitimate business purposes, including providing updates on our products and services. We do not sell or rent your contact information to third parties. By submitting your details, you authorize us to contact you via Call/SMS, even if you are registered under DND. This authorization remains valid for 12 months.For grievances, please contact us at hello@unibrokers.in .